As genetic deletion of Sema4D or Plexin-B1 results in elevated bone mass in mice by promoting osteoblastic bone formation without affecting osteoclastic bone resorption (15), pharmacological inhibition of Plexin-B1 could potentially add a new anabolic principle to osteoporosis treatment. Here, SEMA4D is linked to osteoporosis.